Bellutti Enders F, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017;76(2):329-40. https://www.ncbi.nlm.nih.gov/pubmed/27515057
Dugan E, Huber A, Miller F, Rider L, the International Myositis Assessment and Clinical Studies (IMACS) Group. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatology Online Journal 2009;15(2):1. https://escholarship.org/uc/item/1f04d17z
Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis 2013;16(5):561-7. https://www.ncbi.nlm.nih.gov/pubmed/24164844
Ig Governance. Inflammatory myopathies: polymyositis (PM), dermatomyositis (DM) and necrotising autoimmune myopathy (NAM) version 3.2. Criteria for clinical use of immunoglobulin in Australia. Canberra: National Blood Authority. 2020; Accessed Nov 2022. https://www.criteria.blood.gov.au/MedicalCondition/View/2616
Oldroyd AGS, Lilleker JB, Amin T, Aragon O, Bechman K, Cuthbert V, et al. British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy. Rheumatology (Oxford) 2022;61(5):1760-8. https://www.ncbi.nlm.nih.gov/pubmed/35355064
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 2016;387(10019):671-8. https://www.ncbi.nlm.nih.gov/pubmed/26645190
Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain 2019;142(11):e59. https://www.ncbi.nlm.nih.gov/pubmed/31603187
Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology (Oxford) 2021;60(4):1700-7. https://www.ncbi.nlm.nih.gov/pubmed/33024992
